To prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder, physicians are required to complete 8 hours of training in order to apply to the Drug Enforcement Agency for a waiver.

This course will provide prescribers with the full 8 hours of required MAT training.

Nurse Practitioners (NP), Clinical Nurse Specialists (CNS), Certified Registered Nurse Anesthetists (CRNA), Certified Nurse Midwives (CNM) and Physician Assistants (PA) are required to complete 24 hours of training including the 8 hour MAT training.

Participants can obtain eight (8) hours of continuing education units (see pg. 2 for additional information).

At the conclusion of this activity participants should be able to:

- Screen and identify patients with OUD and define evidence-based treatments.
- Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients.
- Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.
- Explain the process of buprenorphine induction as well as stabilization and maintenance.
- Discuss all FDA approved antagonist and agonist medications to treat OUD.
- Discuss basic office protocols including medical record documentation and confidentially.
- Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD.
- Recognize the importance of obtaining a waiver to begin treating patients with OUD.

Monday and Wednesday, December 14 and 16
1 pm - 5 pm each day

Instructors:
Monica Faria, MD & Michael Dekker, DO
Arizona Society of Addiction Medicine

Location:
Online VIA Zoom Meetings

CMEs: 8 hours (free!)

No Cost to Attend

Registration link:

Register Here

AAAP is the DATA 2000 sponsor for this training.

Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Joint Accreditation Statement: In support of improving patient care, this activity has been planned and implemented by the American Academy of Addiction Psychiatry and Arizona State University. American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

In 2020, AAAP also added accreditation from The American Academy of PAs (AAPA), American Psychological Association (APA), Association for Social Work Boards (ASWB) and American Dental Association (ADA).

Interprofessional Continuing Education (IPCE) Designation Statement: This activity was planned by and for the healthcare team, and learners will receive 8 (eight) Interprofessional Continuing Education credits for learning and change.

Physician Designation Statement: American Academy of Addiction Psychiatry designates this live course for a maximum of 8 (eight) AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Designation Statement: American Academy of Addiction Psychiatry is an approved provider of nursing continuing education through AAAP’s Joint Accreditation provider # 4008192. This program is approved for up to 8 Nursing Contact Hours.

PA Designation Statement: American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 8 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.